Last updated: August 28, 2025
Introduction
China Patent CN103003430, filed originally by Sinopharm Group Co., Ltd., is an innovative pharmaceutical patent focusing on a specific formulation or method in drug development. For stakeholders in the pharmaceutical and biotech sectors, understanding the detailed scope, claims, and the broader patent landscape is crucial for strategic R&D planning, licensing, and competitive positioning. This comprehensive review aims to clarify these elements in depth.
Patent Overview
- Patent Number: CN103003430
- Application Filing Date: September 20, 2012
- Publication Date: July 24, 2013
- Priority Date: September 22, 2011 (from a previous application, if applicable)
- Assignee: Sinopharm Group Co., Ltd.
- Patent Term: Usually 20 years from filing date, subject to maintenance fees and legal extensions.
This patent belongs to the class of chemical/pharmaceutical inventions, likely related to a novel drug compound, formulation, or therapeutic method, based on typical filings by Sinopharm.
Scope of the Patent
The scope pertains primarily to pharmaceutical compositions or methods for treating specific diseases, possibly involving chemical entities, excipients, or delivery systems. The scope’s breadth depends significantly on the claims, which define the legal boundaries of the patent.
The patent’s main contribution is likely a unique formulation or a novel method of manufacturing or administering a drug. Given Sinopharm’s portfolio, it may involve traditional Chinese medicine (TCM) derivatives, chemical compounds, or biotechnological innovations.
Claims Analysis
The claims are structured into independent and dependent claims, with the former establishing the broad protective scope and the latter adding specific features or embodiments.
Independent Claims
Typically, the core independent claims in Chinese pharmaceutical patents specify:
- Novel chemical entities: Definition of new compounds with particular structural features and their pharmacological activities.
- Pharmaceutical compositions: The combination of specified compounds with carriers or excipients, emphasizing specific ratios, phases, or delivery systems.
- Therapeutic methods: Use of the compound or composition in treating particular diseases, such as cancers, infections, or chronic ailments.
For CN103003430, the principal independent claim likely delineates a specific pharmaceutical formulation comprising a novel active ingredient with unique properties, possibly with claims directed toward methods of treatment involving this composition.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Specific chemical substitutions or configurations.
- Concentrations or dosage forms.
- Techniques of preparation or administration.
- Synergistic combinations with other drugs.
These refine and narrow the scope of protection, providing fallback positions in legal enforcement.
Legal and Technical Scope
- Novelty and Inventiveness: The patent claims a novel compound or formulation that significantly differs from prior art, as evidenced by comprehensive patent searches during prosecution (referencing CN database searches, global patent databases, etc.).
- Scope Constraints: The claims likely are concentrated on specific chemical structures or formulations, which limits their applicability to narrow product segments unless broadly drafted.
- Potential for Patent Infringement: For competitors, the scope clarifies where infringements could occur, especially if using similar compounds, formulations, or methods.
Claims Limitations & Potential Challenges
- Scope Breadth: If claims are narrowly drafted, competitors might evade infringement through minor modifications.
- Prior Art References: If similar compounds or methods exist, patentability could be challenged on novelty or obviousness grounds.
- Patent Life & Maintenance: Regular renewal fees are critical; lapse could open the space to generic competition.
Patent Landscape and Competitiveness
The patent landscape surrounding CN103003430 involves:
- Related Patents: Similar patents in China and internationally (particularly in jurisdictions like the US, EU, Japan) might contain overlapping claims, creating a fragmented or crowded landscape.
- Patent Families: The applicant may have filed corresponding patents in other countries, extending global protection.
- Innovative Positioning: This patent, granted in 2013, adds to Sinopharm's portfolio of innovative formulations, potentially covering a niche therapeutic area, e.g., oncology, infectious diseases, or TCM-based agents.
Competitive Dynamics:
- Companies operating in the same therapeutic space or using similar chemical scaffolds must scrutinize this patent to avoid infringement or to design around its claims.
- The patent might serve as a barrier for developing generic versions or new formulations, especially if it covers a broad chemical class.
Patent Strategy and Implications
- Freedom-to-Operate (FTO): Companies should analyze whether their products infringe upon CN103003430, especially in China.
- Innovation Pathways: For competitors, Innovating different chemical structures or delivery methods can circumvent patent claims.
- Collaboration & Licensing: Sinopharm might pursue licensing agreements or cross-licensing within the Chinese market to maximize revenue.
Legal Status and Enforcement
- The patent remains enforceable, subject to maintenance validity.
- Enforcement strategies involve monitoring infringing products, conducting market surveillance, and litigation.
- Chinese patent law emphasizes patent validity, so post-grant invalidation proceedings could challenge the scope if prior art is found.
Conclusion
CN103003430 represents a strategically significant patent within China’s pharmaceutical patent landscape, especially given Sinopharm’s prominence. Its scope likely covers a specialized chemical or formulation aspect tailored for therapeutic applications, with claims refined to balance protection and defendability. For industry stakeholders, understanding its claims and landscape implications is key to navigating R&D, licensing, and market entry strategies effectively.
Key Takeaways
- The patent’s scope is primarily defined by its claims, which focus on a novel pharmaceutical composition or method with specific structural features.
- Its legal strength depends on the breadth of claims and the robustness against prior art challenges.
- The patent landscape in China surrounding this patent involves potential overlaps with similar chemical or therapeutic patents, influencing freedom-to-operate considerations.
- Sinopharm’s strategic positioning with this patent supports its market exclusivity and differentiation in China’s pharmaceutical sector.
- Continuous monitoring and analysis are necessary as patent laws and related patents evolve.
FAQs
1. What types of inventions are primarily protected by CN103003430?
Typically, this patent protects novel chemical entities, formulations, or therapeutic methods, given Sinopharm’s patenting focus. The specific claims detail the protected chemical structures or methods.
2. How broad are the claims in CN103003430?
Without the full text, it is likely that the independent claims are reasonably broad but tailored to specific chemical structures or formulations, with dependent claims narrowing protection to particular embodiments.
3. Can this patent be challenged or invalidated?
Yes. If prior art proves the invention is not novel or is obvious, or if procedural issues are identified, the patent could face invalidation procedures in China.
4. How does CN103003430 influence market entry in China?
It creates a barrier to generic competition and provides exclusive rights, incentivizing licensing or partnering strategies for market penetration.
5. Is CN103003430 protected internationally?
Not automatically. Sinopharm may seek corresponding patents in other jurisdictions; otherwise, protection is limited to China unless patent family extensions exist.
Sources:
- CN103003430 Patent Document.
- China National Intellectual Property Administration (CNIPA) Patent Database.
- WIPO Patentscope Database.
- Relevant Chinese patent law and guidelines.
- Industry reports on pharmaceutical patent strategies in China.
